KR20040111348A - 결장 수송체에 의한 치료 화합물의 조작 흡수 - Google Patents

결장 수송체에 의한 치료 화합물의 조작 흡수 Download PDF

Info

Publication number
KR20040111348A
KR20040111348A KR10-2004-7011457A KR20047011457A KR20040111348A KR 20040111348 A KR20040111348 A KR 20040111348A KR 20047011457 A KR20047011457 A KR 20047011457A KR 20040111348 A KR20040111348 A KR 20040111348A
Authority
KR
South Korea
Prior art keywords
conjugate
transporter
agent
plasma membrane
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7011457A
Other languages
English (en)
Korean (ko)
Inventor
저랑노아
컨디케니스씨
갤럽마크에이
Original Assignee
제노포트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제노포트 인코포레이티드 filed Critical 제노포트 인코포레이티드
Publication of KR20040111348A publication Critical patent/KR20040111348A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2004-7011457A 2002-01-24 2003-01-24 결장 수송체에 의한 치료 화합물의 조작 흡수 Withdrawn KR20040111348A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35180802P 2002-01-24 2002-01-24
US60/351,808 2002-01-24
US10/351,291 US20030158254A1 (en) 2002-01-24 2003-01-23 Engineering absorption of therapeutic compounds via colonic transporters
US10/351,291 2003-01-23
PCT/US2003/002206 WO2003065982A2 (en) 2002-01-24 2003-01-24 Engineering absorption of therapeutic compounds via colonic transporters

Publications (1)

Publication Number Publication Date
KR20040111348A true KR20040111348A (ko) 2004-12-31

Family

ID=27737413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7011457A Withdrawn KR20040111348A (ko) 2002-01-24 2003-01-24 결장 수송체에 의한 치료 화합물의 조작 흡수

Country Status (7)

Country Link
US (1) US20030158254A1 (https=)
EP (1) EP1575494A2 (https=)
JP (1) JP2005529847A (https=)
KR (1) KR20040111348A (https=)
AU (1) AU2003244398A1 (https=)
CA (1) CA2473802A1 (https=)
WO (1) WO2003065982A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
JP4395070B2 (ja) * 2002-06-25 2010-01-06 インデックス・ダイアグノスティックス・アクチエボラーグ 潰瘍性大腸炎を診断するための方法およびキット
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
EP1651963A4 (en) * 2003-07-03 2007-03-21 Xenoport Inc MONOCARBOXYLATE TRANSPORTERS EXPRESSED IN CANCER CELLS
US20050158383A1 (en) * 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
EP1677759A1 (en) * 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
US7462459B2 (en) * 2004-01-30 2008-12-09 Xenoport, Inc. LAT1 transporters expressed in blood brain barrier cells
US7452680B2 (en) * 2004-01-30 2008-11-18 Xenoport, Inc. MCT1 transporters expressed in blood brain barrier cells
WO2005117998A2 (en) * 2004-06-04 2005-12-15 Xenoport, Inc. Smvt transporters expressed in cancer cells
RU2365580C2 (ru) 2004-06-04 2009-08-27 Ксенопорт, Инк. Пролекарства леводопа, композиции на их основе и их применения
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20060003362A1 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. ENT1 transporters expressed in cancer cells
WO2005121787A2 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Lat1 transporters expressed in cancer cells
WO2006001986A2 (en) * 2004-06-04 2006-01-05 Xenoport, Inc. Glut3 transporters expressed in cancer cells
US7348276B2 (en) * 2005-03-30 2008-03-25 Fujitsu, Limited Fabrication process of semiconductor device and polishing method
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
TWI403493B (zh) 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽,其組成物,及其用途
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
EP2217564A1 (en) * 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
CA2747253A1 (en) * 2007-12-20 2009-07-02 Index Diagnostics Ab Method and kit for use in the differentiation of ibd and ibs and further distinction between disease types of ibd
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
US9920136B2 (en) 2013-02-13 2018-03-20 Ark Diagnostics, Inc. Posaconazole immunoassays
BR112022026837A2 (pt) * 2020-07-01 2023-01-24 Capsugel Belgium Nv Composição e método dietético

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5563250A (en) * 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ,インコーポレイテッド 調放性粒子の埋包およびカプセル化
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells

Also Published As

Publication number Publication date
CA2473802A1 (en) 2003-08-14
JP2005529847A (ja) 2005-10-06
WO2003065982A2 (en) 2003-08-14
AU2003244398A1 (en) 2003-09-02
US20030158254A1 (en) 2003-08-21
WO2003065982A3 (en) 2005-12-08
EP1575494A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
KR20040111348A (ko) 결장 수송체에 의한 치료 화합물의 조작 흡수
US6984634B2 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
US7919454B2 (en) Methods of treating using conjugates transported by a PEPT2 transporter
US7420002B2 (en) Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7144877B2 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US20080255073A1 (en) Compounds for sustained release of orally delivered drugs
WO2002028882A1 (en) Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US7053076B2 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
EP1343515A1 (en) Compounds for sustained release of orally delivered drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040723

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid